Download: Re-assessing Orphan Drugs After 4 Years of CED

pharma pricing, market access, orphan, drugs


2013’s Pharma Pricing & Market Access Europe included discussions and presentations on topics like the valuing of new medicines and the future of value based pricing, achieving market access for orphan & rare disease products, achieving market for diabetes oncology and primary care products, patient access and flexible pricing schemes.

An important presentation, notable for its discussion about the media and public role in pricing and pharma markets, was given by Martin van der Graaff from the Dutch Healthcare Reimbursement Authority, CVZ entitled “Demonstration and remonstration: re-assessing orphan drugs after 4 years of CED”

Download the presentation and learn about:

  • Problems with Pompe and Fabry re-evaluation after 4 years CED
  • “Outcomes” research
  • Reassessment woes
  • Reimbursement arrangements in some other countries
  • Future challenges

Download the presentation

This coming February London will play host to the 8th Annual Pharma Pricing and Market Access Outlook World Europe. As the world's largest gathering of pharmaceutical pricing, market access and reimbursement professionals the event regularly attracts key members from across the pharma industry and hosts debates, discussions and presentations on the hot topics within pharma pricing and market access.

To get involved, go to our website for more details

Leave a Reply

Your email address will not be published. Required fields are marked *